Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission

Anticancer Research

Volumn 27, Issue 1 B, 2007, Pages 571-574

  Galani, Zacharoula ^a   Viniou, Nora ^a   Kyrtsonis, Marie Christine ^a   Sachanas, Sotirios ^a   Antoniou, Telemachos ^a   Dimopoulou, Maria N ^a   Vassilakopoulos, Theodoros P ^a   Korkolopoulou, Penelope ^a   Nakopoulou, Lydia ^a   Patsouris, Efstratios ^a   Pangalis, Gerassimos A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Extramedullary; Hepatic infiltration; Multiple myeloma; Renal infiltration

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; AMYLOIDOSIS; ANAMNESIS; ARTICLE; BONE ATROPHY; CASE REPORT; CELL DAMAGE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; KIDNEY BIOPSY; KIDNEY CELL; LIVER CELL; MALE; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; RECOMBINANT INBRED STRAIN; REMISSION;

BONE MARROW; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY; LIVER; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; REMISSION INDUCTION;

EID: 33847757851     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK and Harris NL: Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H and Vardiman JW (eds.). Lyon: IARC press, pp. 142-156, 2001.
2. Kazama T, Ng CS and Giralt SA: Multiphasic CT and MRI appearances of extramedullary multiple myeloma involving the stomach, pancreas, and bladder. Clin Imaging 29: 263-265, 2005.
3. Fernandes-Flores A, Fortes J, Smucler A, Orduna M and Pol A: Involvement of the liver by multiple myeloma as nodular lesions: a case diagnosed by fine-needle aspiration and immunochemistry. Diagn Cytopathol 29: 280-282, 2003.
4. Perez-Soler R, Esteban R, Allende C, Salomo T, Julia A and Guardia J: Liver involvement in multiple myeloma. Am J Hematol 20: 25-29, 1985.
5. Thiruvengadam R, Penetrante RB, Goolsby HJ, Silk YN and Bernstein ZP: Multiple myeloma presenting as space-occupying lesions of the liver. Cancer 65: 2784-2786, 1990.
6. Chemlal K, Couvelard A, Grange MJ, Marmuse JP, Charneau C, Launay O, Carbon C and Yeni P: Nodular lesions of the liver revealing multiple myeloma. Leuk Lymphoma 33: 389-392, 1999.
7. Kaur J, Turner JR, Singh P and Al-Katib A: Multiple myeloma in the liver. Am J Hematol 65: 290, 2000.
8. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K and Kohli HS: Renal involvement in multiple myeloma: 10-year study. Ren Fail 22: 465-477, 2000.
9. Herrera GA, Joseph L, Gu X, Hough A and Barlogie B: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Path Lab Med 128: 875-879, 2004.
10. Van Camp B, Durie BGM, Spier C, De Waele M, Vanriet J and Vela I: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 76: 377-382, 1990.
11. Dalton WS: The tumor microenviroment: focus on myeloma. Cancer Tr Rev 29: 11-19, 2003.
12. Huang N, Kawano MM, Harada H, Harada Y, Sakai A, Kuramoto A and Niwa O: Heterogeneous expression of a novel MRC-1 antigen on myeloma cells: possible involvement of MRC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood 82: 3721-3729, 1993.
13. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK and Pangalis GA: Serum syndecan-1,basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 72: 252-254, 2004.
14. Cibeira MT, Rosinol L, Ramiro L, Esteve J, Torrebadell M and Blade J: Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 77: 486-492, 2006.
15. Anagnostopoulos A, Hamilos G, Zorzou MP, Grigoraki V, Anagnostou and Dimopoulos MA: Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk Lymphoma 45: 113-116, 2004.